Table 3.
Biomarker set | AUC | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|
CA125, HE4, CA15.3, CEA, ApoA1, ApoA2 | 0.965 | 90.45 | 93.71 | 89.93 | 94.04 |
CA125, HE4, CYFRA21.1, CA15.3, ApoA1, ApoA2 | 0.965 | 90.45 | 93.01 | 89.86 | 93.42 |
CA125, HE4, ApoA1 | 0.966 | 90.45 | 91.61 | 89.73 | 92.21 |
CA125, HE4, CA15.3, CEA, ApoA1 | 0.966 | 90.45 | 93.01 | 89.86 | 93.42 |
CA125, HE4, CEA, ApoA1, ApoA2 | 0.966 | 90.45 | 93.71 | 89.93 | 94.04 |
CA125, HE4, CYFRA21.1, ApoA1, ApoA2 | 0.966 | 90.45 | 93.01 | 89.86 | 93.42 |
CA125, HE4, CA15.3, TTR, ApoA1 | 0.967 | 90.45 | 91.61 | 89.73 | 92.21 |
CA125, HE4, ApoA1, ApoA2 | 0.967 | 90.45 | 93.71 | 89.93 | 94.04 |
CA125, HE4, CEA, ApoA1 | 0.967 | 90.45 | 91.61 | 89.73 | 92.21 |
CA125, HE4, CA15.3, ApoA1, ApoA2 | 0.970 | 90.45 | 93.71 | 89.93 | 94.04 |
AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; CA125, carbohydrate antigen 125; HE4, human epididymis protein 4; CA15.3, cancer antigen 15-3; CEA, carcinoembryonic antigen; ApoA1, apolipoprotein A1; ApoA2, apolipoprotein A2; CYFRA21.1, cytokeratin fragment 21-1; TTR, transthyretin.